WASHINGTON — A key Senate committee on Wednesday voted to require drug companies to justify price hikes to the federal government if they exceed 10% in a year or 25% in a three-year span, advancing a proposal that also enjoys bipartisan support in the House.

The measure, spearheaded by Sen. Tammy Baldwin (D-Wis.), was offered as an amendment to a broader health care bill being considered by the Senate’s Health, Education, Labor, and Pensions Committee. Three other senators — two Republicans and one Democrat — co-sponsored the legislation, which the committee voted to include by a 16-7 margin.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy